Back to results
US 5,508,044 AGranted
Diltiazem pharmaceutical spheroid formulation
AssigneeEuro-Celtique S.A.
InventorsIan R. Buxton, Adrian Brown, Helen Critchley, Stewart T. Leslie, Sandra T. A. Malkowska, Derek A. Prater, Ronald B. Miller
Life of this patent
Estimating the term…
Abstract
A solid oral dosage form comprising diltiazem (or a pharmaceutically acceptable salt thereof) in controlled release form and hydrochlorothiazide in immediate release form. Preferably, the controlled release component comprises a plurality of spheroids comprising diltiazem and a spheronizing agent.
Claims2
A solid oral dosage form for the treatment of hypertension in humans, comprising
- a core comprising a plurality of spheroids comprising diltiazem or pharmaceutically acceptable salt thereof, and a spheronizing agent, wherein said diltiazem or pharmaceutically acceptable salt thereof is present in an amount effective to render an antihypertensive effect, said core including a water-insoluble material selected from the group consisting of a wax, an alkylcellulose and a polymethacrylate in an amount effective to prolong the release of said diltiazem over a desired period of time when said dosage form is contacted with water or digestive fluids, wherein said spheroids are coated with a controlled release film coating comprising from about 50% to about 95% ethylcellulose, from about 5% to about 15% dibutyl sebacate, and from about 5% to about 15% polysorbate 80;
- and
- an immediate release coating on said core including an effective amount of hydrochlorothiazide to render a diuretic effect when said dosage form is contacted with water or digestive fluids.
A solid oral dosage form for the treatment of hypertension in humans, comprising
- a plurality of beads comprising diltiazem or a pharmaceutically acceptable salt thereof in an amount effective to render an antihypertensive effect, and a controlled release coating in an amount effective to provide a controlled release of said diltiazem or pharmaceutically acceptable salt thereof when said composition is exposed to aqueous solutions, said controlled release coating comprising from about 50% to about 95% water insoluble material selected from the group consisting of a wax, an alkylcellulose and a polymethacrylate, from about 1% to about 25% plasticizer, from about 1% to about 25% surfactant, and from about 1% to about tack-modifier;
- and
- an immediate release outer coating comprising effective amount of hydrochlorothiazide to render a diuretic effect, the weight ratio of diltiazem or its pharmaceutically acceptable salt to hydrochlorothiazide being from about 30:1 to about 4:1.
Dependencies are inferred from the claim text.